KCM
CSTL icon

Kornitzer Capital Management’s Castle Biosciences CSTL Stock Holding History

Kornitzer Capital Management’s Portfolio CSTL Stock Details CSTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$6.49M Sell
264,396
-3,337
-1% -$109K 0.14% 151
2025
Q4 		$10.4M Sell
267,733
-10,581
-4% -$341K 0.22% 108
2025
Q3 		$6.34M Hold
278,314
– – 0.13% 190
2025
Q2 		$5.68M Hold
278,314
– – 0.11% 214
2025
Q1 		$5.57M Sell
278,314
-105,660
-28% -$2.62M 0.11% 211
2024
Q4 		$10.2M Sell
383,974
-23,264
-6% -$709K 0.2% 143
2024
Q3 		$11.6M Sell
407,238
-135,636
-25% -$3.45M 0.21% 131
2024
Q2 		$11.8M Hold
542,874
– – 0.22% 125
2024
Q1 		$12M Hold
542,874
– – 0.22% 138
2023
Q4 		$11.7M Sell
542,874
-105,350
-16% -$1.85M 0.23% 135
2023
Q3 		$10.9M Hold
648,224
– – 0.23% 137
2023
Q2 		$8.89M Hold
648,224
– – 0.17% 190
2023
Q1 		$14.7M Sell
648,224
-68,020
-9% -$1.66M 0.29% 98
2022
Q4 		$16.9M Buy
716,244
+92,048
+15% +$2.13M 0.34% 80
2022
Q3 		$16.3M Sell
624,196
-17,316
-3% -$485K 0.35% 74
2022
Q2 		$14.1M Buy
641,512
+197,170
+44% +$4.58M 0.28% 113
2022
Q1 		$19.9M Hold
444,342
– – 0.33% 99
2021
Q4 		$19M Buy
444,342
+100,525
+29% +$5.25M 0.28% 124
2021
Q3 		$22.9M Hold
343,817
– – 0.35% 86
2021
Q2 		$25.2M Buy
343,817
+77,940
+29% +$5.15M 0.38% 82
2021
Q1 		$18.2M Buy
265,877
+92,115
+53% +$6.92M 0.29% 126
2020
Q4 		$11.7M Buy
173,762
+13,387
+8% +$726K 0.2% 177
2020
Q3 		$8.25M Buy
160,375
+24,895
+18% +$1.11M 0.16% 197
2020
Q2 		$5.11M Buy
+135,480
New +$4.63M 0.1% 249

Other funds holding CSTL

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $187B AUM 18.48% 1-Year Est. Return
PCM
Portolan Capital Management Boston, Massachusetts $1.88B AUM 115.74% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
SPPAM
Summit Partners Public Asset Management Boston, Massachusetts $3.72B AUM 162.29% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Allianz Asset Management
Allianz Asset Management Munich, Germany $95.4B AUM 38.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Kornitzer Capital Management's CSTL Position: Q1 2026 in Review

Kornitzer Capital Management reduced its Castle Biosciences (CSTL) stake by 1.2% in Q1 2026, selling an estimated $109K and leaving 264,396 shares worth $6.49M. The position accounts for 0.14% of the portfolio, ranked #151.

Kornitzer Capital Management first reported a position in CSTL in Q2 2020 and has held it in 24 quarters since. The position peaked at $25.2M in Q2 2021. 186 funds tracked by Wall St. Rank hold CSTL as of Q1 2026.

  • Kornitzer Capital Management held 264,396 shares of Castle Biosciences worth $6.49M as of Q1 2026.
  • Kornitzer Capital Management sold 3,337 Castle Biosciences shares in Q1 2026, an estimated $109K.
  • Castle Biosciences made up 0.14% of Kornitzer Capital Management's portfolio in Q1 2026, its #151 holding.
  • Kornitzer Capital Management first reported a position in Castle Biosciences in Q2 2020 and has held it in 24 quarters since.
  • Kornitzer Capital Management's Castle Biosciences position peaked at $25.2M in Q2 2021.
  • 186 funds tracked by Wall St. Rank held Castle Biosciences as of Q1 2026.

Based on Kornitzer Capital Management's 13F filing for Q1 2026, filed 30 Apr 2026.